Carbidopa And Levodopa has 18 known drug interactions based on U.S. FDA drug labeling data. Of these, 8 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mao Inhibitors, Mao Inhibitors (Type A Or B), Metoclopramide. Patients taking Carbidopa And Levodopa should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 18
- Contraindicated
- 8
- Major
- 2
- Moderate
- 7
- Minor
- 1
Contraindicated (8)
- Carbidopa And Levodopa + Mao Inhibitors— Contraindicated in patients receiving MAO inhibitors (Type A or B).
- Carbidopa And Levodopa + Mao Inhibitors (Type A Or B)— Contraindicated per drug label.
- Carbidopa And Levodopa + Metoclopramide— 7 DRUG INTERACTIONS Iron salts and dopamine D2 antagonists including metoclopramide: May reduce the effectiveness of car…
- Carbidopa And Levodopa + Phenelzine— Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to i…
- Carbidopa And Levodopa + Reserpine— Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic…
- Carbidopa And Levodopa + Selegiline— Concomitant therapy may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alo…
- Carbidopa And Levodopa + Tetrabenazine— Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic…
- Carbidopa And Levodopa + Tranylcypromine— Nonselective MAO inhibitor use with carbidopa and levodopa is contraindicated. Discontinue at least two weeks prior to i…
Major (2)
- Carbidopa And Levodopa + Papaverine— The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by papaverine.
- Carbidopa And Levodopa + Phenytoin— The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin.
Moderate (7)
- Carbidopa And Levodopa + Butyrophenones— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
- Carbidopa And Levodopa + Iron Salts— Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailabilit…
- Carbidopa And Levodopa + Isoniazid— May reduce the therapeutic effects of levodopa; patients should be carefully observed for loss of therapeutic response.
- Carbidopa And Levodopa + Phenothiazines— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
- Carbidopa And Levodopa + Rasagiline— Selective MAO-B inhibitor may be associated with orthostatic hypotension when used concurrently; monitor patients.
- Carbidopa And Levodopa + Risperidone— Dopamine D2 receptor antagonists may reduce the therapeutic effects of levodopa; patients should be carefully observed f…
- Carbidopa And Levodopa + Selegiline Hydrochloride— Selective MAO-B inhibitor may be used concomitantly with carbidopa/levodopa, but concomitant therapy may be associated w…
Minor (1)
- Carbidopa And Levodopa + Ropinirole— Co-administration had no effect on ropinirole steady-state pharmacokinetics. Ropinirole increased L-dopa Cmax by 20% but…